Advertisement


Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement



May
11
Today In Oncology
Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?
FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer
More From the FDA ODAC Votes on Agents for Pretreated Hepatocellular Carcinoma and Gastric Cancer
Increased Loneliness Among Patients With Cancer During the COVID-19 Pandemic May Affect Symptom Burden
One vs Two Doses of the BNT162b2 COVID-19 Vaccine in Patients With Cancer: Immunogenicity and Efficacy
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside